Wendy's Rejects Trian's $1.4B Offer; Marvel Deal Widens; Baker Brothers Buy Biotech
Summary
The hosts discuss the closure of the Marvel Technology-Lumentum acquisition, noting significant stock dilution and arbitrage activity that widened the deal spread. They analyze Wendy's rejection of Trian Fund Management's $1.4 billion offer, attributing the decision to CEO Robert Wright's confidence in his turnaround strategy at Potbelly. The episode then highlights Baker Brothers' insider purchases in Madrigal Pharmaceuticals and Kodiak Sciences, focusing on the therapeutic advantages of their respective drug platforms. Finally, the speakers address Madrigal's recent stock drop due to a whistleblower lawsuit, noting that Baker Brothers doubled down on their position despite the allegations.
Key takeaways
- 1 A wide headline spread (e.g., 18%) can be misleading if the deal timeline is long (e.g., mid-2028), resulting in a much lower annualized yield (e.g., 11%).
Unidentified speaker (speaker_0) · 3:32
Episode sections
- 0:55 – 4:31
Lumentum/Marvel Technology Deal Closure
The hosts discuss the finalization of the all-stock acquisition of Lumentum by Marvel Technology, noting it as the second-largest deal of the year. They highlight the significant drop in Marvel's stock due to dilution and merger arbitrageurs shorting the share, which widened the deal spread to nearly 18%.
- 4:31 – 9:58
Wendy's Rejection of Trian's Offer
Wendy's rejected a $1.4 billion cash offer from Trian Fund Management at $7.35 per share and adopted a poison pill, causing its stock to rise to $8.15. The hosts attribute this to CEO Robert Wright's recent turnaround success at Potbelly and his desire to continue operating Wendy's rather than accepting a 'take-under' offer.
- 9:58 – 18:28
Baker Brothers Insider Purchases in Biotech
The episode shifts to insider buying trends, highlighting Baker Brothers' recent purchases of Madrigal Pharmaceuticals and Kodiak Sciences. The hosts analyze the specific therapeutic advantages of Madrigal's Resdifra over Novo Nordisk's Wigovi and Kodiak's ABC platform against competitors like Regeneron's ILEA.
- 18:28 – 22:38
Madrigal Whistleblower Lawsuit and Market Reaction
Madrigal faced an 8% stock drop following a whistleblower lawsuit alleging hidden liver injury data and trial manipulation. Despite the allegations and shareholder investigations, the Baker Brothers doubled down on their position, signaling strong confidence in the company's prospects.
Claims worth verifying
The Lumentum/Marvel Technology deal was an all-stock acquisition and the second-largest deal announced in the year, behind the $130 billion acquisition of NextEra Energy by Dominion Energy.
Unidentified speaker (speaker_0) ·1:34
How to verify: SEC EDGAR filings for Marvel Technology and Lumentum (Form S-4 or Proxy Statement) and news archives for deal size rankings in 2026. For recent events, verify 2026-08-09 through 2026-11-09. Use another period only when the speaker explicitly names it.
Primary sourceThe deal was originally valued at close to $115 billion but the value decreased due to stock declines.
Unidentified speaker (speaker_0) ·1:52
How to verify: SEC EDGAR filings for Marvel Technology detailing the exchange ratio and initial valuation. For recent events, verify 2026-08-09 through 2026-11-09. Use another period only when the speaker explicitly names it.
Primary sourceThe Nasdaq dropped more than 5% on the Thursday following the deal announcement.
Unidentified speaker (speaker_0) ·2:12
How to verify: Nasdaq Composite index historical data for the week of the deal announcement (late October 2026). For recent events, verify 2026-08-09 through 2026-11-09. Use another period only when the speaker explicitly names it.
The spread on the Marvel/Lumentum deal widened to nearly 18% by Friday.
Unidentified speaker (speaker_0) ·3:32
How to verify: Merger arbitrage tracking services (e.g., InsideArbitrage, DealMeters) or calculation of the spread between Marvel's stock price and the deal terms. For recent events, verify 2026-08-09 through 2026-11-09. Use another period only when the speaker explicitly names it.
The expected close date for the Marvel/Lumentum deal is mid-2028.
Unidentified speaker (speaker_0) ·3:32
How to verify: SEC EDGAR filings for Marvel Technology (Form S-4) stating the expected closing date. For recent events, verify 2026-08-09 through 2026-11-09. Use another period only when the speaker explicitly names it.
Primary sourceWendy's rejected a $1.4 billion offer from Trian Fund Management at $7.35 per share in cash.
Unidentified speaker (speaker_0) ·4:51
How to verify: SEC EDGAR filings for Wendy's (Schedule 14D-9 or Proxy Statement) and press releases from Trian Fund Management dated around the rejection. For recent events, verify 2026-08-09 through 2026-11-09. Use another period only when the speaker explicitly names it.
Primary sourceWendy's stock rose to $8.15 after adopting a poison pill triggered by acquisitions over 15%.
Unidentified speaker (speaker_0) ·5:11
How to verify: Wendy's SEC filings (Schedule 14D-9) disclosing the poison pill and stock price data from financial terminals for the week of the announcement. For recent events, verify 2026-08-09 through 2026-11-09. Use another period only when the speaker explicitly names it.
Primary sourceTrian owns 16.3% of Wendy's stock.
Unidentified speaker (speaker_0) ·5:11
How to verify: SEC EDGAR filings for Wendy's (Schedule 13D/G) filed by Trian Fund Management. For recent events, verify 2026-08-09 through 2026-11-09. Use another period only when the speaker explicitly names it.
Primary sourceRobert Wright joined Potbelly and oversaw its sale to Racetrack for $566 million.
Unidentified speaker (speaker_0) ·6:31
How to verify: SEC EDGAR filings for Potbelly (Form S-4 or Proxy) regarding the acquisition by Racetrack. For recent events, verify 2026-08-09 through 2026-11-09. Use another period only when the speaker explicitly names it.
Primary sourceMadrigal's drug Resdifra crossed the $1 billion in annual sales threshold.
Unidentified speaker (speaker_2) ·17:28
How to verify: Madrigal Pharmaceuticals earnings reports or press releases confirming sales milestones. For recent events, verify 2026-08-09 through 2026-11-09. Use another period only when the speaker explicitly names it.
Do your own research
- Verify the exact deal timeline and regulatory approval status for the Marvel-Lumentum transaction to calculate accurate annualized yield.
- Review Wendy's proxy statements and poison pill details to understand shareholder rights and the specific terms of Trian's rejected offer.
- Analyze the full text of the Madrigal whistleblower lawsuit to assess the validity of the alleged hidden liver injury data.
- Check Baker Brothers' 13F filings to confirm the size and timing of their Madrigal and Kodiak positions.
- Compare the clinical trial data for Resdifra and Wigovi to evaluate the claimed therapeutic advantages for MASH patients.
- Review FDA correspondence for Kodiak Sciences regarding the Daybreak trial and upcoming submissions.
- Assess the regulatory environment for semiconductor M&A deals involving Chinese authorities to gauge potential delays.
- Examine historical stock performance of Wendy's to determine if the $7.35 offer was indeed a 'take-under' relative to historical highs.
Full transcriptexpand
- 0:05
- Unidentified speaker (speaker_0): Hello and welcome to episode 76 of the Special Situations Report, a podcast by Inside Arbitrage covering the most intriguing event-driven activity over the past week. My name is Asib Surya.
- 0:18
- Tamanna Suria: And my name is Tamana Surya.
- 0:20
- Unidentified speaker (speaker_0): And if you've been listening to this podcast, please take a moment to help us spread the word by liking or subscribing to. this podcast on whatever platform you may be listening on.
- 0:30
- Tamanna Suria: Today we wanted to focus on two key stories, including Wendy's decision to adopt a poison pill in response to the offer from Trion and two insider purchases at the biotech focused investment firm, Baker Bros. Before we begin, we want to state that nothing on this podcast is meant as investment advice. We or our clients may have a position in any of the
- 0:49
- Tamanna Suria: stocks discussed today. Please refer to our full disclaimer at the end of the podcast for more details.
- 0:55
- Unidentified speaker (speaker_0): Let's kick off this podcast with a potential deal or a deals in the work situation as we like to call them. But before we get into the details of Wendy's decision to turn down the acquisition when Nelson Peltz Trion Fund Management, let us briefly touch upon a deals in the work situation from last week that turned into an active
- 1:14
- Unidentified speaker (speaker_0): actual merger. Last Monday, just minutes before Tamana was done uploading this podcast to multiple different platforms, including YouTube, the deal for Lumentum, which was an acquisition by Marvel Technology that we discussed in detail last week, was finalized. This was an all-stock deal, which made it the second
- 1:34
- Unidentified speaker (speaker_0): largest deal announced this year, behind the $130 billion. acquisition of Next Era Energy by Dominion Energy, and a little bit ahead of Paramount's massive deal to acquire Warner Brothers Discovery. So the deal, when it was announced, I think was close to $115 billion.
- 1:52
- Unidentified speaker (speaker_0): But because the stock of both these companies fell, they're trading well below that level. And so the deal is no longer valued at $115 billion. As we discussed last week, Marvel's stock had already taken a pretty hard hit when the rumor of this deal surfaced. And then that decline continued pretty much most of last week after
- 2:12
- Unidentified speaker (speaker_0): the deal was confirmed. It certainly didn't help that the Nasdaq dropped more than 5% last Thursday after the Democrats gained control of Congress, which in turn sparked fears that it would translate into a slowdown in data center build-out. and this whole AI bull market that we've been experiencing. The other technical thing to keep
- 2:32
- Unidentified speaker (speaker_0): in mind is that the acquiring company stock usually drops a lot when a large deal like this is announced. And this is not just because shareholders of the acquiring company will be diluted, but if merger arbitragers want to step in and capture the spread on the deal, they will shock. short the acquiring company
- 2:52
- Unidentified speaker (speaker_0): stock. So there's a technical downward pressure on the acquiring company stock. And that's what we saw with Marvel. I remember something very similar to this happening to Gilead's stock when it acquired the Hepsi drug company PharmaSet a very long time ago, probably more than 10 years ago. And that was the first time I saw how much an acquiring
- 3:12
- Unidentified speaker (speaker_0): company stock can drop because of both these mechanisms. shareholder dilution as well as merger arbitragers stepping in to short the stock of the acquiring company. The spread on the momentum deal was already wide at nearly 13% when this deal was announced and then widened throughout the week to end at nearly
- 3:32
- Unidentified speaker (speaker_0): 18% by Friday. The timeline to close the deal is also very long, with the a mid-2028. mid 2028 close expected. And hence the annualized return is not as attractive as the headline 18% spread turns out to be. And the annualized yield is closer to 11%.
- 3:49
- Tamanna Suria: Why might the timeline be so long on this deal?
- 3:52
- Unidentified speaker (speaker_0): Yeah, so to begin with, it's a very large deal. And then on top of that, it is international approvals, which can take quite some time. And especially in the past, we've seen that some semiconductor deals tend to trade at a widespread. And that is because China often drags its feet when it comes to semiconductor mergers. There was one merger
- 4:12
- Unidentified speaker (speaker_0): where they dragged their feet so much that the acquiring company just decided to give up and move on. And then after the fact, they came out and said, Yeah, we would approve this merger. So when it comes to semiconductor deals, for the better part of a decade or more, they always tend to. trade with a larger spread because the expected timeline to close is usually extended.
- 4:31
- Unidentified speaker (speaker_0): Moving on from this Marvel technology deal, and for full disclosure, I do own stock of Marvel technology both in my personal portfolio and we also have it in the inside arbitrage model portfolio. But let's switch gears and talk about Wendy's. We were a little surprised when the fast food chain turned down RIAN's Trion's offer for $7.30. $7.35 per
- 4:51
- Unidentified speaker (speaker_0): share in cash. And even more surprised when the stock jumped to $8.15 by the end of the week, when the company adopted a poison pill provision that gets triggered if a person or a group acquires more than 15% of the company. So normally when there is an offer on the table and the company that is going to be acquired
- 5:11
- Unidentified speaker (speaker_0): decides not to take the offer, you see the stock drop. But we saw something reverse happen with Wendy's and the stock went up. Trian already owns 16.3% of Wendy's stock, and they were working with the Flynn Group, Blue Fi Capital, and Sixth Street Partners on their $1.4 billion offer for Wendy's. Wendy's stock was trading at
- 5:31
- Unidentified speaker (speaker_0): around $9 per share a year ago, and at about $23 per share five years ago, making that $7. $7.35 offer by Trion a significant take under. So, sure, there was some premium to reason prices, but when you think of it over the last year or over the last five years, this was very much a take
- 5:51
- Unidentified speaker (speaker_0): under. While revenue growth has slowed down over the last year, I think it was a little negative last quarter. The company is still solidly profitable. And in most quarters, free cash flow is. well ahead of reported gap net income. The rejection also makes sense when you look at what is happening in Wendy's C-suite. And I think Tamana,
- 6:11
- Unidentified speaker (speaker_0): you pointed this out to me as we were looking at this, right? You were like, check out the CEO's track record, not really track record, check out the CEO's career and what has happened. And that was really entertaining when I started taking a look at it when you pointed it out. CEO Robert Wright. joined the company less than six months ago, having spent the prior five years
- 6:31
- Unidentified speaker (speaker_0): at potbellies until it sailed to Racetrack in a $566 million deal. The potbelly deal was at a nice 32% premium, but that is just the cherry on the top. And as we will get to it, Robert Wright did a phenomenal job at Portbelly. Port Belly. The new CFO of Wendy's, who joined just a month after Robert.
- 6:51
- Unidentified speaker (speaker_0): Wright took over as CEO, was also from Portbellies. So basically, the CEFO he was used to working with, he pulled him into Wendy's after he joined. When we started taking a look at Robert Wright, we found that his career was absolutely fascinating. He actually started his career at Domino's as a franchise consultant and then joined
- 7:10
- Unidentified speaker (speaker_0): Wendy's in the late 1990s for nearly seven years, rising to the position of Director of Operations. He then ran a subsidiary of Wendy's called Cafe Express for two years before returning to the mothership as VP of Operations. He left Wendy's to join the management team of two other restaurant chains
- 7:30
- Unidentified speaker (speaker_0): before returning to Wendy's for a second time as its chief operating officer. In the middle of the pandemic in 2020, he left once again to become the CEO of Portbellies when the stock was trading at just $3 per share. He stayed until it's sale to Racetrack for $17.12, driving significant shareholder
- 7:50
- Unidentified speaker (speaker_0): returns during his five-year tenure. And so I was also looking at other metrics. And not only did he help make sure that the stock price went up, but he did that because revenue went up quite significantly after he took over and the company. went from being unprofitable to solidly profitable. So real operations turnaround that drove the stock price.
- 8:10
- Unidentified speaker (speaker_0): This time around, it is his third stint at Wendy's, and he's back as in the role of CEO. And in that context, it actually makes sense that he and a CFO wanted to gain some traction for Wendy's before potentially considering selling the offer. So it makes sense. they decided to turn down Trion's offer and want to continue
- 8:30
- Unidentified speaker (speaker_0): operating the company. I really wish more management teams operated like this instead of giving up and accepting a take under offer that tends to hurt long-term shareholders.
- 8:41
- Tamanna Suria: Yes, Bumble for example comes to mind as an example of a take under that was terrible for long-term shareholders. It was acquired by Itaka Holdings for $1.3 billion. which valued the company at roughly 90.7% below its former peak valuation of approximately $14 billion from its 2021 public market debut.
- 9:00
- Unidentified speaker (speaker_0): Yeah, but that's interesting, right? If you remember late 2020 and 2021 was a mini bubble of its own during the COVID-19 pandemic and event IPO during that period, we got involved as a pre-deal situation, so we doubled our money on that. this. But even as we did that, you know, it it was at the back of my mind, as somebody did
- 9:20
- Unidentified speaker (speaker_0): point out to me on Twitter, that long term shareholders have not fared very well with this company. So in that sense, I really commend what the CEO and CFO of Enties are doing. And I'm actually getting interested, even though investing in a On fast food chain wouldn't be normally top of mind for me.
- 9:36
- Unidentified speaker (UNKNOWN): Yeah,
- 9:36
- Tamanna Suria: it's interesting to see how much our perspective changed from. why did Wendy's reject this deal to I'm so glad they didn't.
- 9:42
- Unidentified speaker (speaker_0): Absolutely. And and the credit goes to you for drawing my attention to it. That's why we do this together. We we enjoy looking at things differently.
- 9:49
- Tamanna Suria: Absolutely. And it was fun to see how the CEO would pop back in and pop back out of Wendy's every couple of years. That was, I think, my biggest takeaway. Moving on to other big takeaways.
- 9:58
- Unidentified speaker (speaker_2): On our recent podcast episode with Jesse Felder, we spoke extensively about incident. insider activity and how signals from insider purchases have changed greatly over the last decade or two. Rather than keeping an eye out for insider purchases at any one business, insider activity seems to be the best signal when you look at themes, such as insider buying and selling in
- 10:18
- Unidentified speaker (speaker_2): aggregate, which we track every week in our insider weekends articles. Other patterns that we like to look for are independent directors with an investing background. and or deep industry experience purchasing shares, or founder CEOs who have remained with the business through multiple market cycles buying stock. Another broad pattern that we like to see is insider buying
- 10:38
- Unidentified speaker (speaker_2): across an industry. Since we got out of the biotech nuclear winter, or the regional bank crisis, seeing multiple regional banks or biotech companies pop up on our list of insider purchases for the daily event-driven wander. wanderer is such a normal occurrence. And since we've seen such elevated levels of insider activity at biotech businesses over the last year, I
- 10:58
- Unidentified speaker (speaker_2): feel like we've started to pick up on insider-related patterns within the industry itself, right? The most significant of these patterns is seeing the same biotech-focused investors in funds pop up across multiple businesses, such as RA Capital Management, Kevin Tang of Tang Capital Management, and the Baker Bros. And it was none other than the Baker Bros. who returned this week with not just
- 11:18
- Unidentified speaker (speaker_2): one, but two purchases at two different companies that topped our list of insider purchases this week Madrigal Pharmaceuticals and Kodiak Sciences. If you've been keeping up with Insider Arbitrage for quite some time, both these names might be familiar. But let me explain what it is exactly both these biotechs
- 11:34
- Unidentified speaker (UNKNOWN): do
- 11:34
- Unidentified speaker (speaker_2): briefly. Madrigal Matrigal is focused on treating metabolic dysfunction associated steatohepatitis, better known as MASH, a progressive liver disease that can lead to cirrhosis, liver failure, and death. Founded in 2006, the company achieved a major milestone in 2024 by becoming the first company to receive U.S.
- 11:54
- Unidentified speaker (speaker_2): FDA approval to treat MASH via its therapy REST Resdifra. IFRA. Until mid mid-August August 2025, Matrigal Magigal enjoyed exclusivity in this market. but on August 15th, 2025, the FDA approved Novo Nordis GLP1 drug, Wigovi, to treat MASH in adults with moderate to advanced fibrosis.
- 12:13
- Unidentified speaker (speaker_0): So are there any key differences between Vigovi and maybe even Ilalili's drugs and ResDifra?
- 12:19
- Unidentified speaker (speaker_2): Well, good for Magigal, there's quite a few, which has led to its more dominant position in the market. Res Rest Difra diffra is an oral tablet. as opposed to Wigovi's injection, which is a lot easier on patients and has a liver-specific drug mechanism, whereas Wigovi is primarily meant to regulate glucose and appetite, with liver benefits as a secondary effect of overall weight
- 12:39
- Unidentified speaker (speaker_2): loss. Wigovi tends to improve mash through anti-inflammatory effects and by reducing fat levels in liver.
- 12:46
- Unidentified speaker (speaker_0): But wasn't a pill version of Vigovi released not too long ago? now?
- 12:51
- Unidentified speaker (speaker_2): Absolutely, and that's still for its GLP1 standard treatment. I believe the indication for MASH is still an injection. So that's where Restifera still wins out. Restifera wins out on another angle as well, actually, as Vigovi is meant for new MASH patients who have metabolic characteristics of the disease, such as obesity and cardiovascular
- 13:11
- Unidentified speaker (speaker_2): disease, and who are not currently receiving medication to manage those. comorbidities. However, since many patients with MASH are already taking some GLP1 drug, Residifera is more suitable as they are considered to be lean already. Furthermore, the liver-directed nature of Residifra makes it a more suitable treatment for patients with advanced fibrosis. And now
- 13:31
- Unidentified speaker (speaker_2): for Kodiak. Kodiak is a pre-commercial retina-focused biotechnology company that is working to treat the leading causes of blindness. globally. Kodiak's antibody biopolymer conjugate drug platform, better known as the ABC Platform, serves as the core of the company's discovery engine and uses molecular engineering to merge the fields
- 13:51
- Unidentified speaker (speaker_2): of protein-based and chemistry-based therapies. Kodiak's portfolio is characterized by three late stage clinical medical programs, two of which are derived from this ABC system.
- 14:00
- Unidentified speaker (UNKNOWN): The
- 14:00
- Unidentified speaker (speaker_2): therapies cover a wide range of retinal
- 14:03
- Tamanna Suria: diseases, including wet age
- 14:05
- Unidentified speaker (speaker_2): macular degeneration, known as wet
- 14:07
- Tamanna Suria: AMD,
- 14:08
- Unidentified speaker (speaker_2): diabetic retinopathy, known as DR,
- 14:11
- Tamanna Suria: and more. Essentially, to
- 14:13
- Unidentified speaker (speaker_2): sum these diseases up because they're quite jargon-heavy, if blood vessels in the retina are damaged, blocked, or inflamed,
- 14:19
- Tamanna Suria: they may leak fluid or grow
- 14:21
- Unidentified speaker (speaker_2): abnormally,
- 14:22
- Tamanna Suria: causing swelling that can lead to vision loss
- 14:24
- Unidentified speaker (speaker_2): or blindness if left
- 14:25
- Tamanna Suria: untreated. Kodiak seeks to provide
- 14:27
- Unidentified speaker (speaker_2): that very
- 14:28
- Tamanna Suria: treatment. Kodiak
- 14:29
- Unidentified speaker (speaker_2): is not alone in its mission to address this myriad of retinal diseases, and key drugs from competitors include Vabismo, developed by Roche, and ILEA, developed by Regeneron and Bayer. Interestingly enough, we discovered both these businesses, Kodiak and Madrigal, through insider purchases by the Baker Bros. They purchased shares of Madrigal back in August 2025 and
- 14:49
- Unidentified speaker (speaker_2): purchased shares of Kodiak in early October 2026, which is why it was a bit surprising to see them double down and purchase shares of Kodiak again last week, alongside their purchase of Madrigal stock.
- 14:59
- Unidentified speaker (speaker_0): Perhaps briefly, can you talk a little bit about Baker Brothers? Because we come across them so often and have tracked them for the longest period of time as one of the best biotech focused funds out there. They really are the GOATs, if you will, of biotech.
- 15:14
- Unidentified speaker (speaker_2): Absolutely. So the Baker Bros, the hedge fund itself, was founded in 2000 by brothers Julian and Felix Baker and is known for its extreme secrecy. So though we've been able to track them for decades due to their insider purchases and tracking the Form 4s, otherwise they're pretty private. They notably avoid the press at all costs. And the fund
- 15:34
- Unidentified speaker (speaker_2): itself has no real website or online presence. In 1994, the pair started. managing healthcare investments for the Tisch family, the namestake behind the NYU Tisch School and the family best known for turning the theater and chain, Lowe's, into a massive conglomerate. The Bakers created a standalone business in 2000, and within six years they
- 15:53
- Unidentified speaker (speaker_2): oversaw $1 billion as an exclusively biotech-focused Tech focused investment firm. As it stands today, the Baker Brothers Advisors has an AUM of 22%. $28.15 billion. And Madrigal and Kodiak make up some of their largest holdings in the fund, at least from the information that we can derive from their 13Fs and major insider
- 16:13
- Unidentified speaker (speaker_2): activity. Felix Baker has served as one of Kodiak's directors since September 2015, while Julian Baker is the chairman of Madrigal's board.
- 16:21
- Unidentified speaker (speaker_0): So what might be encouraging them to suddenly purchase shares of both these businesses now?
- 16:26
- Unidentified speaker (UNKNOWN): Well,
- 16:26
- Unidentified speaker (speaker_2): that's a million dollar question, isn't it?
- 16:29
- Unidentified speaker (UNKNOWN): The
- 16:29
- Unidentified speaker (speaker_2): Kodiak purchase is especially interesting because it's so close to their $157 million purchase in October. So I assume the catalysts haven't changed all that much from last time. They purchased shares last nearly immediately after positive results from Kodiak's Daybreak trial, a major late-stage trial that demonstrated that two of its drugs worked as well
- 16:49
- Unidentified speaker (speaker_2): as ILA, ILEA, the leading treatment. for wet AMD, which is a common age-related cause of vision loss. The brothers also bought ahead of several milestones for Kodiak, who plans to ask the FDA to approve its lead drug, Sancuta, for three different indications by the fourth quarter of 2026, and is testing whether or not a second drug can beat
- 17:08
- Unidentified speaker (speaker_2): ILEA in diabetes-related eye swelling, and expects results in an FDA filing for a third drug in mid-1980s. mid-2027. There's quite the buying opportunity here, considering that ILEA bought in about $7.9 billion in sales last year, and its manufacturer, Regeneron, is worth about $73 billion. Matrigal is perhaps more interesting. Since
- 17:28
- Unidentified speaker (speaker_2): the firm's purchase of stock of the company in August 2025, Residifera has officially become a blockbuster drug, crossing the $1 billion in annual sales threshold. The drug has also received European approval and is officially launched in Germany, with other EU member states working on price and reimbursement negotiations with the company. The company
- 17:48
- Unidentified speaker (speaker_2): has expanded its platform quite significantly as well. The pipeline now includes a combination of RISDFR and a couple different drugs, such as a pill that blocks the liver from making fat, a GLP 1 pill that drives weight loss, or gene silencing SI. siRNA therapies, which switch off a gene variant that speed up liver disease. More importantly though,
- 18:08
- Unidentified speaker (speaker_2): Restifera is also being evaluated for the treatment of mash cirrhosis, the furthest progression of the mash disease that results in severe permanent scarring of the liver. That drug is currently in a phase three trial and expects a top top-line line readout in late 2027. But not all the Madrigald magical news is positive. Michael Charlton,
- 18:28
- Unidentified speaker (speaker_2): Madrigal's former head of clinical development, filed a whistleblower lawsuit in early October 2026, alleging that the company hid liver injury safety data for Restifra, presented cirrhosis trial results that couldn't be matched to the underlying data, and pushed him out after he raised concerns.
- 18:48
- Unidentified speaker (speaker_2): Madrigald Madrigal denies the allegations and plans to fight the suit, but the stock fell about 8% on November 3rd when the suit was officially disclosed, and law firms have since opened investigations on behalf of shareholders. City analysts found no unusual liver risk compared to similar drugs of the FDA's adverse event database, but stock still
- 19:07
- Unidentified speaker (speaker_2): fell about 8% on each of two consecutive days after the suit was disclosed. However, even if the drug itself is safe, these concerns about the trial process and the data process are quite significant and could mess up the company's top line readout expected in late 2027 for the F4 or most advanced stage of cirrhosis data.
- 19:26
- Unidentified speaker (speaker_0): Fascinating situation overall, but I can see why the Baker brothers are doubling down. That is quite a signal of confidence from them after this information came out. But we should also mention that the other person.
- 19:39
- Unidentified speaker (speaker_0): the famous GOAT, if you will, in the merger arbitrage space, John Paulson, who now manages his own money, he doesn't manage external money, has madrigal pharmaceuticals as his top position. I think you've written both about material pharmaceuticals and perpetual resources. And perpetual used to be his largest position in the fund, and madrigal
- 19:59
- Unidentified speaker (speaker_0): the second one, but more recently, because perpetua's Purpicho's price went down. Madrigal has become his largest position. So you have two GOATs in two different fields that own Madrigal. And it'll be interesting to see what happens once this whistleblower lawsuit things settle down. But quite frankly, I'm quite fascinated by the other one, not as much by
- 20:19
- Unidentified speaker (speaker_0): Madrigal as I am by Kodiak. It just feels like you know the fact that they're willing to buy the stock at $30, $33, what were whatever that price might have been, and are now buying at $90 and now close to $100 just shows that they're willing to double down at three times the price and have that level of confidence in that company.
- 20:37
- Unidentified speaker (speaker_2): Absolutely. And Caudiac itself, I think, is a fascinating story, just seeing how the stock prices performed or even the company has performed over the years. I believe it was in 2023 when they had two massive trial failures. And they've kind of climbed their way back since then. And that's quite encouraging to see. And it's encouraging even more to see that the Baker Bros are supporting them throughout the entire journey.
- 20:56
- Unidentified speaker (speaker_0): That's right. You you mentioned that in your write up about how this company was pretty much down in the dumps after those failures and it's come up so much. And they remain confident. And that's why they are such wonderful investors in the biotech space. I think they do the deep research and have the scientific background to understand what's happening in these companies.
- 21:14
- Tamanna Suria: Absolutely. We always joke that
- 21:16
- Unidentified speaker (speaker_2): biotech companies are outside our circle of competence, but our circle of competence does include insider purchases, so we get to piggyback off insider purchases like these.
- 21:25
- Unidentified speaker (speaker_0): Indeed.
- 21:25
- Unidentified speaker (UNKNOWN): And
- 21:26
- Unidentified speaker (speaker_2): with that, we will wrap up episode 75 of the Special Situations Report. What we've covered today is just a brief overview of the Special Situations landscape. So if you'd like to access a more comprehensive weekly overview of all event-driven advent driven activity, go ahead and visit our website, thespecial situationsreport.com. For daily updates and alerts on the special situations world, as well as access to
- 21:45
- Unidentified speaker (speaker_2): tools to help you identify opportunities such as the merge archage tool, check out InsideArpage.com.
- 21:51
- Unidentified speaker (speaker_0): And if you enjoyed this podcast and our discussion of both Madrigal as well as Kodiak, please take a moment to like and subscribe on whatever platform you may be listening on. And especially share it with your friends who are interested in
- 22:02
- Unidentified speaker (UNKNOWN): the world.
- 22:03
- Unidentified speaker (speaker_0): special situations. Thank you.
- 22:05
- Unidentified speaker (speaker_2): We also wanted to provide a reminder that this podcast is for general informational and educational purposes only. The content does not constitute financial, investment, legal, or tax advice. We do not warrant the completeness or accuracy of the content or data provided in this podcast. We or our clients may hold a position in any of the companies discussed discuss in this podcast. Nothing discussed today should be interpreted as a
- 22:25
- Unidentified speaker (speaker_2): recommendation to buy, sell, or hold. any investment for security. Investing involves substantial risks, including the potential loss of principal. You should conduct your own research and due diligence before making any investment decisions. Thank you.